Clinical experience with rosuvastatin in the management of hyperlipidemia and the reduction of cardiovascular risk

Stephen J. Nicholls, Kiyoko Uno, Yu Kataoka

Research output: Contribution to journalArticleResearchpeer-review

7 Citations (Scopus)


On the basis of large randomized clinical trials, pharmacological antagonists of HMG-CoA reductase (statins) have become increasingly used in clinical practice for the prevention of cardiovascular disease. Rosuvastatin was developed as a potent statin, which appeared to raise levels of HDL-cholesterol, in addition to marked reductions in levels of LDL-cholesterol. These effects on lipids are associated with a beneficial impact of rosuvastatin on progression of various stages of atherosclerosis and cardiovascular outcomes in clinical trials. The clinical experience of rosuvastatin will be reviewed in this article.

Original languageEnglish
Pages (from-to)1383-1390
Number of pages8
JournalExpert Review of Cardiovascular Therapy
Issue number11
Publication statusPublished - 1 Nov 2011
Externally publishedYes


  • atherosclerosis
  • cardiovascular disease
  • clinical trials
  • lipids
  • risk factors
  • rosuvastatin

Cite this